EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineered nanobiotechnology for cancer immunotherapy

Chengqiong Mao, Yang Liu, Jun Wang

Science Bulletin · 2026-10

DOI: 10.1016/j.scib.2026.10.062 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Bulletin, 2026-10. Verfasst von Chengqiong Mao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital,…. Die Arbeit nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the clinical success of immune checkpoint blockade and chimeric antigen receptor T-cell therapies, solid tumors frequently remain poorly responsive due to multi-step failures in initiating, maintaining, and executing immune responses in vivo. Overcoming these barriers requires organizing immune cues into productive biological relationships rather than simply intensifying systemic immune stimulation. This review examines how engineered nanobiotechnology addresses this central challenge by spatially and temporally coordinating key immune processes. Adopting a biology-driven and engineering-enhanced perspective, we analyze nanoscale interventions across four critical phases of antitumor immunity. Immune initiation engineering optimizes antigen processing and localized delivery to promote productive T-cell priming. To sustain these responses, targeted nanosystems reprogram lymphocytes and myeloid cells toward functional effector states in vivo. At the cellular interface, engineered platforms spatially coordinate immune recognition and effector engagement, while tumor microenvironment (TME) engineering remodels the suppressive niche to support tumor-specific immune activation. By organizing these advances through a process-centered engineering framework, we elucidate how nanobiotechnology can convert otherwise localized, transient, or poorly coordinated immune stimulation into integrated antitumor immunity. Finally, we discuss emerging clinical examples and translational requirements, highlighting how pharmacodynamic immune readouts, patient stratification, and manufacturable designs will drive next-generation nano-immunotherapies toward solid-tumor treatment.

Schlagwörter

Stichwörter der Autor:innen

Cancer immunotherapyImmune reprogrammingNanobiotechnologyTumor microenvironment

Autor:innen und Institutionen

  • Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, School of Biomedical Engineering, Guangzhou Medical University, Guang…
  • School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China; National Engineering Research Center for Tissue Restoration and Reconstructio…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Mao, C., Liu, Y., & Wang, J. (2026). Engineered nanobiotechnology for cancer immunotherapy. Science Bulletin. https://doi.org/10.1016/j.scib.2026.10.062

Vancouver

Mao C, Liu Y, Wang J. Engineered nanobiotechnology for cancer immunotherapy. Science Bulletin. 2026. doi:10.1016/j.scib.2026.10.062

BibTeX
@article{Mao2026,
  author = {Mao, Chengqiong and Liu, Yang and Wang, Jun},
  title = {Engineered nanobiotechnology for cancer immunotherapy},
  journal = {Science Bulletin},
  year = {2026},
  doi = {10.1016/j.scib.2026.10.062}
}
Kostenlos starten →